Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-
about
Cancer concepts and principles: primer for the interventional oncologist-part IMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerSurrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsXELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.Multiple treatment comparison meta-analyses: a step forward into complexity.Clinical and experimental study of oxaliplatin in treating human gastric carcinomaInternational guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?Individual- and trial-level surrogacy in colorectal cancer.Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.Treatment and survival from breast cancer: the experience of patients at South Australian teaching hospitals between 1977 and 2003
P2860
Q26851255-F909DB31-7A61-461B-9912-2B0F47381E60Q26860469-7E6D0153-A429-4D24-B589-D25A5F6A41EFQ33600372-43A84AE2-9DD5-423E-8A06-107DB88DB58EQ34630237-5C002306-A023-4102-BD6A-55138F532357Q35089776-27A73401-8C67-40BF-9F2B-CC2964EF9D8BQ36065649-406291AB-323E-4B90-8C09-6E4E5EB44B99Q37329165-1830B1D6-32F6-42B3-8EC7-B9434620C256Q37760357-DA5DAFA7-926C-419E-B730-8D67B6A12DACQ37952239-6DCE23F7-E39A-48E9-84EE-F2656DA13145Q38389980-081F614A-C068-4B57-97E5-CBF14DA72EC6Q40122418-BB4F19C1-06E4-4F68-9548-1E1E500B34DFQ42921489-D6076137-8063-4F36-B90D-CFC7FEC5E886Q46855579-EA665A0A-12B0-4CC0-B5F9-5C8D0DE938E4Q57586364-333CABC5-8746-4C24-9683-6C6275CEABF6
P2860
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Is overall survival a realisti ...... with oxaliplatin or with CPT-
@ast
Is overall survival a realisti ...... with oxaliplatin or with CPT-
@en
type
label
Is overall survival a realisti ...... with oxaliplatin or with CPT-
@ast
Is overall survival a realisti ...... with oxaliplatin or with CPT-
@en
prefLabel
Is overall survival a realisti ...... with oxaliplatin or with CPT-
@ast
Is overall survival a realisti ...... with oxaliplatin or with CPT-
@en
P356
P1433
P1476
Is overall survival a realisti ...... ith oxaliplatin or with CPT-11
@en
P2093
P304
P356
10.1093/ANNONC/MDH127
P577
2004-04-01T00:00:00Z